216 related articles for article (PubMed ID: 25770292)
1. CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
Pabla N; Sparreboom A
Clin Cancer Res; 2015 Mar; 21(6):1237-9. PubMed ID: 25770292
[TBL] [Abstract][Full Text] [Related]
2. Ixabepilone: a new microtubule-targeting agent for breast cancer.
Higa GM; Abraham J
Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
[TBL] [Abstract][Full Text] [Related]
3. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
4. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
5. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
Brogdon CF; Lee FY; Canetta RM
Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
[TBL] [Abstract][Full Text] [Related]
6. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
7. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ixabepilone, a novel epothilone analogue.
Pivot X; Dufresne A; Villanueva C
Clin Breast Cancer; 2007 Apr; 7(7):543-9. PubMed ID: 17509162
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
Lopus M; Smiyun G; Miller H; Oroudjev E; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1013-24. PubMed ID: 26416565
[TBL] [Abstract][Full Text] [Related]
10. Preclinical investigations with epothilones in breast cancer models.
Burris HA
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S15-21; quiz S39. PubMed ID: 18410795
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
[TBL] [Abstract][Full Text] [Related]
12. Application of epothilones in breast cancer therapy.
Cianfrocca M
Curr Opin Oncol; 2008 Nov; 20(6):634-8. PubMed ID: 18841044
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
15. Microtubule-binding natural products for cancer therapy.
Yue QX; Liu X; Guo DA
Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.
De Luca A; D'Alessio A; Maiello MR; Gallo M; Chicchinelli N; Pergameno M; Piccirilli MS; Normanno N
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1177-85. PubMed ID: 26073581
[TBL] [Abstract][Full Text] [Related]
17. Clinical studies with epothilones for the treatment of metastatic breast cancer.
Vahdat LT
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes.
Andreopoulou E; Muggia F
Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S54-60. PubMed ID: 18637400
[TBL] [Abstract][Full Text] [Related]
19. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]